Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
4.80
Dollar change
-0.14
Percentage change
-2.83
%
IndexRUT P/E- EPS (ttm)-1.30 Insider Own8.04% Shs Outstand41.53M Perf Week-0.41%
Market Cap208.46M Forward P/E- EPS next Y-0.51 Insider Trans0.00% Shs Float39.94M Perf Month-23.57%
Income-46.05M PEG- EPS next Q-0.47 Inst Own29.60% Short Float5.63% Perf Quarter-20.40%
Sales27.46M P/S7.59 EPS this Y-21.79% Inst Trans-5.35% Short Ratio9.05 Perf Half Y0.63%
Book/sh1.49 P/B3.22 EPS next Y68.11% ROA-31.99% Short Interest2.25M Perf Year-20.92%
Cash/sh0.99 P/C4.84 EPS next 5Y- ROE-62.37% 52W Range3.89 - 7.28 Perf YTD-26.72%
Dividend Est.- P/FCF- EPS past 5Y51.89% ROI-68.34% 52W High-34.07% Beta1.85
Dividend TTM- Quick Ratio1.18 Sales past 5Y44.97% Gross Margin85.61% 52W Low23.39% ATR (14)0.30
Dividend Ex-Date- Current Ratio1.18 EPS Y/Y TTM-7.51% Oper. Margin-180.63% RSI (14)33.20 Volatility5.63% 5.08%
Employees69 Debt/Eq0.71 Sales Y/Y TTM162.58% Profit Margin-167.69% Recom1.00 Target Price18.00
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q-52.95% Payout- Rel Volume0.85 Prev Close4.94
Sales Surprise12.51% EPS Surprise-90.09% Sales Q/Q469.94% EarningsMar 28 AMC Avg Volume248.58K Price4.80
SMA20-12.22% SMA50-19.75% SMA200-8.48% Trades Volume211,067 Change-2.83%
Date Action Analyst Rating Change Price Target Change
Apr-02-24Reiterated Maxim Group Buy $12 → $18
Mar-12-24Initiated William Blair Outperform
Mar-17-23Initiated Maxim Group Buy $12
Apr-10-24 07:30AM
Apr-01-24 12:46PM
Mar-29-24 12:07PM
Mar-28-24 09:52PM
06:11PM
04:53PM Loading…
04:53PM
04:32PM
Mar-26-24 04:30PM
Mar-25-24 04:30PM
Mar-21-24 10:00AM
Mar-18-24 07:30AM
Mar-07-24 11:56AM
Mar-04-24 07:30AM
Feb-28-24 07:30AM
Feb-15-24 03:49AM
07:30AM Loading…
Feb-06-24 07:30AM
Jan-23-24 07:30AM
Jan-08-24 07:30AM
Jan-04-24 08:55AM
Dec-27-23 07:30AM
Nov-20-23 07:30AM
Nov-12-23 08:42AM
Nov-07-23 08:17AM
07:08AM
07:00AM
Oct-31-23 07:30AM
Oct-19-23 07:30AM
Oct-10-23 07:30AM
Oct-05-23 07:30AM
Oct-02-23 07:30AM
07:30AM Loading…
Sep-20-23 07:30AM
Sep-09-23 08:00PM
Sep-05-23 07:30AM
Sep-04-23 09:55AM
Sep-01-23 07:31AM
Aug-31-23 12:13PM
07:30AM
Aug-19-23 07:40AM
Aug-17-23 09:55AM
Aug-15-23 12:15AM
Aug-14-23 07:42AM
07:30AM
Aug-07-23 04:45PM
Aug-02-23 07:30AM
Jul-19-23 10:30AM
07:30AM
Jun-20-23 07:30AM
Jun-13-23 07:30AM
Jun-03-23 07:30AM
May-16-23 06:22AM
May-15-23 05:55PM
04:59PM
04:05PM
May-10-23 07:30AM
May-09-23 07:30AM
May-08-23 07:30AM
May-03-23 07:30AM
Apr-17-23 04:05PM
06:18AM
Apr-04-23 07:30AM
Mar-30-23 07:30AM
Mar-17-23 07:30AM
Mar-15-23 07:26AM
Mar-07-23 07:00AM
Mar-06-23 07:30AM
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson ThomasDirectorSep 06 '23Buy4.8810,00048,76410,000Sep 06 04:39 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerSep 06 '23Buy4.961,0004,95915,309Sep 06 05:11 PM
Bode John BDirectorSep 05 '23Buy5.1310,00051,33320,000Sep 06 04:40 PM
Schafer JoshuaCCO & EVP, Bus. DevelopmentSep 05 '23Buy5.135002,5643,500Sep 06 05:11 PM
Watton Corey MichaelDirectorJun 23 '23Buy5.952751,6361,000Jun 26 04:19 PM
Watton Corey MichaelDirectorJun 09 '23Buy5.523251,794725Jun 13 08:35 PM
Watton Corey MichaelDirectorMay 30 '23Buy5.114002,042400May 31 11:34 AM
Schafer JoshuaCCO & EVP, Bus. DevelopmentMay 19 '23Buy5.421,0005,4163,000Jun 30 04:14 PM
Bode John BDirectorMay 18 '23Buy5.0410,00050,41810,000May 19 05:53 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerMay 18 '23Buy4.952,74013,56213,742May 18 04:56 PM